I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post ...
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
India Today on MSN2d
Benefits outweigh risks: Novo Nordisk India's MD on Ozempic side effectsVikrant Shrotriya, Novo Nordisk India's Managing Director, addressed concerns over the side effects of Ozempic during a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback